0.063
-0.001
(-1.56%)
Delayed:
11:52AM GMT+10
ASX
data delayed by 20 mins -
Disclaimer
Currency in AUD
| Range | 0.06 - 0.06 |
| 52 week | 0.02 - 0.07 |
| Open | 0.06 |
| Vol / Avg. | 682,870.00/9.72M |
| Mkt cap | 74.52M |
| P/E | - |
| Div/yield | - |
| EPS | 0.00 |
| Shares | 1.18B |
| Beta | - |
| Inst. own | - |
Events
May 27, 2013
NEUREN PHARMACEUTICALS LTD Annual General Meeting
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -125.60% | -117.15% |
| Operating margin | -125.60% | -117.15% |
| EBITD margin | - | -105.78% |
| Return on average assets | -55.33% | -51.66% |
| Return on average equity | -70.87% | -62.17% |
| Carbon Disclosure Rating | - | - |
Address
Level 1 59 Wellington Street, Freemans Bay PO Box 9923
AUCKLAND, NSW 1001
New Zealand
+64-9-3700200 (Phone)
+64-9-3617981 (Fax)
AUCKLAND, NSW 1001
New Zealand
+64-9-3700200 (Phone)
+64-9-3617981 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Neuren Pharmaceuticals Limited is a New Zealand-based company. The Company is a biopharmaceutical company focusing on the development of drugs for neurological disorders and cancer. In neurology, the drugs target both acute indications, such as traumatic brain injury and concussion, as well as chronic conditions, such as autism spectrum disorders and neurodegenerative diseases. In oncology, the focus is on developing monoclonal antibodies to treat breast and other cancers. The Company has three lead candidates, which include NNZ-2566 and Motiva in clinical development to treat a range of acute and chronic neurological conditions, and NNZ-2591 in preclinical development for chronic neurodegenerative conditions. The Company has operations in New Zealand and the United States.
Officers and directors
| Richard Treagus MBA | Executive Chairman of the Board | |
| Larry Glass | Chief Executive Officer, Managing Director | |
| Joseph Horrigan | Vice President - Clinical Development and Medical Affairs | |
| Nancy E. Jones | Senior Director of Clinical Development and Medical Affairs | |
| Robert Waring | Company Secretary | |
| Bruce Alan Hancox | Independent Non-Executive Director | |
| John W. Holaday Ph.D. | Independent Non-Executive Director | |
| Graeme B. Howie Ph.D. | Independent Non-Executive Director | |
| Trevor D. Scott | Independent Non-Executive Director |